No registrations found.
ID
Source
Brief title
Intervention
Background summary
Male patients with FD will undergo a [123I]IBZM SPECT scan to assess the number of striatal dopaminergic D2 receptors. Two hours later a brainscan (lasting 50 minutes)
will be made.
Study objective
N/A
Intervention
Single dose of 185 MBq [123I]IBZM intravenously. As controlgroup an existing file of healthy male volunteers will be used.
P.O. Box 22660
G.E.E. Boeckxstaens
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5667375
g.e.boeckxstaens@amc.uva.nl
P.O. Box 22660
G.E.E. Boeckxstaens
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5667375
g.e.boeckxstaens@amc.uva.nl
Inclusion criteria
1. Nepean Dyspepsia Index (NDI) score >= 25;
2. >18 years of age.
Exclusion criteria
1. Use of drugs that affect gastrointestinal motility (antidepressants, opiates, NSAID’s, calcium-blockers, nitrates);
2. use of drugs that can affect binding of the radioligand to dopamine D2 receptors (neuroleptics, dopamine D2 agonists, anti-vertigo-drugs metoclopramide, alizapride);
3. IBS;
4. previous abdominal surgery;
5. history of myocardial infarct or CVA;
6. epilepsy;
7. severe liver or renal insufficience;
8. depression;
9. claustrophobia.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL28 |
| NTR-old | NTR49 |
| Other | : N/A |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |